Galmed Pharma Secures New Patent for NASH Drug Combo
Ticker: GLMD · Form: 6-K · Filed: Mar 15, 2024 · CIK: 1595353
| Field | Detail |
|---|---|
| Company | Galmed Pharmaceuticals LTD. (GLMD) |
| Form Type | 6-K |
| Filed Date | Mar 15, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent, pharmaceuticals, NASH, intellectual-property
TL;DR
Galmed just got a new patent for Aramchol + Rezdiffra combo for NASH. IP protection boosted.
AI Summary
On March 15, 2024, Galmed Pharmaceuticals Ltd. announced the grant of a new patent for the combination of their drug Aramchol with Resmetirom (Rezdiffra) for treating NASH and liver fibrosis. This patent extends the company's intellectual property protection for this potential therapeutic combination.
Why It Matters
This patent strengthens Galmed's intellectual property position, potentially enhancing the commercial viability of their NASH treatment strategy by protecting a combination therapy.
Risk Assessment
Risk Level: medium — The filing is a routine announcement of a patent grant, which is generally positive but doesn't involve immediate financial transactions or significant operational changes.
Key Players & Entities
- Galmed Pharmaceuticals Ltd. (company) — Registrant
- Aramchol (drug) — Drug in combination therapy
- Resmetirom (drug) — Drug in combination therapy
- MGL-3196 (drug) — Alternative name for Resmetirom
- REZDIFFRA (drug) — Brand name for Resmetirom
- NASH (medical_condition) — Condition to be treated
- March 15, 2024 (date) — Date of announcement
FAQ
What is the primary purpose of the press release attached to this Form 6-K?
The press release announces the grant of a new patent for the combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH and liver fibrosis.
What is the exact date of the announcement by Galmed Pharmaceuticals Ltd.?
The announcement was made on March 15, 2024.
What is the exact name of the company filing this report?
The exact name of the company is Galmed Pharmaceuticals Ltd.
What is the ticker symbol or commission file number for Galmed Pharmaceuticals Ltd.?
The commission file number is 001-36345.
What specific medical conditions is the patented drug combination intended to treat?
The patented drug combination is intended for the treatment of NASH (Non-alcoholic steatohepatitis) and liver fibrosis.
Filing Stats: 246 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2024-03-15 09:13:13
Filing Documents
- form6-k.htm (6-K) — 17KB
- ex99-1.htm (EX-99.1) — 13KB
- 0001493152-24-010019.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: March 15, 2024 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer